Bone Abstracts

PTH replacement therapy in hypoparathyroidism (hypoPT) has become more accepted after proving successful in several clinical studies. Intact PTH (PTH1–84) was in 2012 withdrawn, leaving teriparatide (PTH1–34) the only therapeutic option available.All patients with postoperative HypoPT who changed medication from PTH1–84 (100 μg) to PTH1–34 (20 μg), after at least 12 months of conve...

It has been previously reported that prolonged treatment with rhPTH(1–34) or rhPTH(1–84) in rats is associated with the development of bone neoplasms including osteosarcomas. However, to date there has been no evidence of an increased osteosarcoma risk of in patients treated with rhPTH(1–34) or rhPTH(1–84), or in diseases associated with chronic PTH elevation. Abaloparatide (ABL) is a novel analog of PTHrP(1–34) currently being developed as a treatment...

Objective: Mobility is an important endpoint in patient care with implications for activities of daily living, community participation, and quality of life. We adapted the performance-oriented mobility assessment (POMA-G),1 a widely used and validated clinical gait assessment tool for adults, to use in children with hypophosphatasia (HPP). HPP is the rare metabolic disease caused by loss-of-function mutation(s) in the gene encoding tissue non-specific alkaline phosp...

Abaloparatide (BA058) is a synthetic analog of PTHrP1–34 which greatly increases bone mass and bone strength with preservation of normal bone quality in animal models of osteoporosis. Daily s.c. abaloparatide (ABLSC) at doses of up to 80 μg daily in postmenopausal women with osteoporosis for up to 48 weeks were associated with increases in spine and femoral neck BMD of up to 12.9 and 4.1% respectively and good safety and tolerability. The increa...

Patients with hypoparathyroidism lack sufficient parathyroid hormone (PTH) and exhibit reduced bone turnover, abnormally increased bone mineral density (BMD), and abnormal bone microarchitecture. Current treatment regimens fail to address underlying PTH deficiency. In the REPLACE phase III trial, treatment with rhPTH(1–84) restored mineral homeostasis, increased bone turnover markers (BTMs), and decreased BMD in patients with hypoparathyroidism.REPE...

Hypoparathyroidism results in low bone turnover and increased bone mineral density (BMD). Replacing deficient PTH with rhPTH(1–84) has the potential to correct these skeletal abnormalities. To investigate the effect of rhPTH(1–84) on BMD and bone turnover markers (BTMs), data from two studies were assessed.REPLACE, a double-blind, multicenter, placebo-controlled study, randomized 134 patients with hypoparathyroidism to receive once-daily rhPTH(...

Evidence is unclear on the effect of vitamin D intake on vitamin D status in children.Objective: In a meta-analysis, investigate the effect of vitamin D supplements and/or fortified foods on vitamin D status, using the biomarker 25-hydroxyvitamin D (25(OH)D) in children 2–18 years.Methods: Eligible studies were randomized placebo-controlled trials, published in English, in children 2–18 years that compared vitamin D suppl...

Introduction: The availability of bone turnover markers (BTMs) that are kidney independent has facilitated the monitoring of bone turnover in renal patients with hyperparathyroid bone disease. The effects of Cinacalcet on BTMs and on the relationship between parathyroid hormone (PTH) and BTMs were studied.Methods: The formation marker procollagen type 1 N propeptide (P1NP) and resorption marker tartrate resistant acid phosphatase 5b (TRACP5b) were measur...

Osteoprotegerin gene (OPG) is an important candidate gene of osteoporosis. Association of the OPG polymorphisms and bone mineral density (BMD) have been studied by several research groups, however results are not uniform.The aim of this study was to determine if two polymorphisms in the OPG gene influence bone turnover markers and bone mineral density (BMD) in postmenopausal women and elderly men. A total of 135 patients, aged 41–87 years, were incl...

Introduction: Bisphosphonates gain increasingly greater significance in treatment oncologic diseases with bone metastasis. However, a lot of articles have lately been published in dental and oncological journals on jaw osteonecrosis (ONJ) associated with long-term ingestion of bisphosphonates. Besides extension of clinical recommendations for zolendronate use, most commonly referred to in connection with ONJ, for treatment of Paget’s diseaseand other disturbances of bone ...